Consistent with this, therapies blocking Ang II activity such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) effectively lower blood pressure, reduce risk for diabetes, prevent deficits in cardiovascular and metabolic functions and increase lifespan in aged animals and clinical populations [7,9,10,11]. Here, ACE is linked to diabetes mellitus.